Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci

Department of Pathology, Chinese People's Liberation Army General Hospital, Beijing, China.
Cancer Science (Impact Factor: 3.52). 05/2011; 102(5):1107-11. DOI: 10.1111/j.1349-7006.2011.01894.x
Source: PubMed


Currently, CD133 is one of the best markers to characterize cancer stem cells and Her-1 is reported as an important marker for the prognosis of triple-negative breast cancer. To investigate the relationship between the expression of CD133 and Her-1 and clinicopathology as well as prognosis in triple-negative breast cancer, 67 cases of triple-negative invasive ductal breast carcinoma taken from 422 patients with breast cancer were analyzed by immunohistochemistry and clinicopathology with follow-up. The CD133 and Her-1 were expressed as positive in 43.3% (29/67) and 53.7% (36/67) of patients, respectively. The expression of CD133 corresponded to tumor size (P = 0.022), clinical stage (P = 0.001) and lymphatic metastasis (P = 0.001), but not to age and histological grade. By Kaplan-Meier analysis the expression of CD133 was correlative with overall survival (OS) (log rank = 9.346, P = 0.002) and disease free survival (DFS) (log rank = 38.840, P = 0.0001) time of breast cancer patients. The expression of Her-1 was corresponding to tumor size (P = 0.031), clinical stage (P = 0.005) and lymphatic metastasis (P = 0.002), but not to age and histological grade. By Kaplan-Meier analysis the expression of Her-1 was correlative with overall survival (OS) (log rank = 7.998, P = 0.005) and DFS (log rank = 4.227, P = 0.040) time of patients with cancer. It is concluded that the expression of CD133 and Her-1 may be correlative with prognosis in triple-negative breast cancer.

  • Source
    • "A commonly investigated potential CSC marker is CD133 (also known as prominin-1), a 120 kDa five transmembrane domain cell surface glycoprotein, which was initially considered to be one marker of hematopoietic stem cells [5,6]. Now, CD133 may represent a putative cancer stem cell marker in many solid tumors, such as human colon cancer [7,8], breast cancer [9,10], gastric cancer [11,12], glioblastoma [13], lung cancer [14,15], liver cancer [16,17], pancreatic cancer [18], prostate cancer [19], and cholangiocarcinoma [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Presently, CD133 is one of the hottest markers to characterize cancer stem cells and KAI1/CD82 is reported as an important marker for the metastasis and prognosis of many cancers. The purpose of our study is to explore the relationship between cancer stem cells (CSCs) marked by CD133 and KAI1/CD82 expression and the clinicopathological characteristics of patients with laryngeal squamous cell carcinoma (LSCC). Immunohistochemical analysis was used to detect the expression of CD133 and KAI1/CD82 in 83 archival surgical specimens of human LSCC and 83 cases of normal laryngeal tissues. In LSCC, positive rates of 49.4% and 41.0% were obtained for CD133 and KAI1/CD82, respectively. The expression of CD133 in LSCC tissues was significantly higher than that in normal tissues (P < 0.001), and the expression of CD133 was positively associated with pTNM stage (P = 0.005), pathological grade (P = 0.001), and lymph node metastasis (P < 0.001). The reduced expression of KAI1/CD82 was present in LSCC tissues. The positive rate of KAI1/CD82 expression was negatively correlated with pTNM stage (P = 0.014), pathological grade (P < 0.001), and lymph node metastasis (P = 0.007). A correlation analysis showed that there was a negative relationship between the expression of CD133 and KAI1/CD82 protein in LSCC tissues (P < 0.001). By Kaplan-Meier analysis, the expression of CD133 was negatively correlated with overall survival (OS) (log-rank = 40.949, P < 0.001) and disease-free survival (DFS) (log-rank = 39.307, P < 0.001) time of LSCC. The expression of KAI1/CD82 was positively correlated with OS (log-rank = 40.279, P < 0.001) and DFS (log-rank = 39.271, P < 0.001) time of LSCC. Cox regression analysis: the expression of CD133 and KAI1/CD82, and pTNM stages were independent prognostic factors of LSCC (P < 0.05). Thus the detection of CD133 and KAI1/CD82 proteins may be used as a potential indicator of LSCC prognosis.
    Full-text · Article · Apr 2014 · World Journal of Surgical Oncology
  • Source
    • "Triple-negative breast cancers (TNBC), as defined on the basis of immunohistochemistry and for typically being negative for estrogen receptor (ER), progesterone receptor (PR) and HER2, represent approximately 20% of all breast tumors and have a considerable clinical relevance as they primarily affect young women, appear resistant to conventional chemotherapy regimens, have a particularly poor prognosis and a significantly worse clinical outcome than other tumor types [2]. In the management of patients with TNBC, a promising role seems to be played by the observed relationship between the positivity to the glycosylated trans-membrane protein CD133 and shorter disease free and overall survival, suggesting that CD133 expression may be of help in more accurately predicting the aggressive properties of this neoplasia [3]. Although a wide range of studies suggest that CD133-positivity identifies cancer stem cells [4] yet the ability of CD133 to reliably identify breast tumor progenitors is controversial, also due to the use of different antibodies recognizing CD133 splice variants with epitopes of different glycosylation status [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Beyond its possible correlation with stemness of tumor cells, CD133/prominin1 is considered an important marker in breast cancer, since it correlates with tumor size, metastasis and clinical stage of triple-negative breast cancers (TNBC), to date the highest risk breast neoplasia. To study the correlation between the levels of CD133 expression and the biology of breast-derived cells, CD133low and CD133high cell subpopulations isolated from triple negative MDA-MB-231 cells were compared in terms of malignant properties and protein expression. High expression of CD133 characterizes cells with larger adhesion area, lower proliferation rate and reduced migration speed, indicative of a less undifferentiated phenotype. Conversely, when compared with CD133low cells, CD133high cells show higher invasive capability and increased expression of proteins involved in metastasis and drug-resistance of breast tumors. Among the signalling proteins examined, PLC-beta2 expression inversely correlates with the levels of CD133 and has a role in inducing the CD133high cells to CD133low cells conversion, suggesting that, in TNBC cells, the de-regulation of this PLC isoform is responsible of the switch from an early to a mature tumoral phenotype also by reducing the expression of CD133. Since CD133 plays a role in determining the invasiveness of CD133high cells, it may constitute an attractive target to reduce the metastatic potential of TNBC. In addition, our data showing that the forced up-regulation of PLC-beta2 counteracts the invasiveness of CD133-positive MDA-MB-231 cells might contribute to identify unexplored key steps responsible for the TNBC high malignancy, to be considered for potential therapeutic strategies.
    Full-text · Article · Dec 2013 · Molecular Cancer
  • Source
    • "Originally, CD133 was known as a surface marker of hematopoietic stem cells and progenitor cells, but CD133 has also recently been reported as a marker of CSCs in solid cancers such as brain tumors [2], lung cancer [3], liver cancer [4], colon cancer [5, 6], pancreatic cancer [7], and prostate cancer [8]. In addition, in lung cancer [9], breast cancer [10], hepatocellular carcinoma [11], colon cancer [12], and pancreatic cancer [13], CD133 expression has been reported to be strongly related not only to tumor progression, but also to treatment resistance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background CD133 is one of the most important stem cell markers in solid cancers. Some recent reports have described a possible relationship between CD133 and hypoxia-inducing factor-1-alpha (HIF-1α). The aim of this study was to clarify the clinical role of CD133 expression in gastric cancer and to investigate the correlation between CD133 expression and HIF-1α expression. Methods We studied 189 gastric cancer patients who underwent gastrectomy at Kurume University Hospital. CD133 and HIF-1α expression was examined using immunohistochemical staining. Fifty-six cases were CD133 positive, and they were divided into two expression types: luminal expression of the gland and cytoplasmic expression. We investigated the relationship among CD133 expression types, clinicopathological variables, prognosis, and HIF-1α expression. Results When comparing clinicopathological variables, expression of CD133 in the cytoplasm was related to metastasis and tumor progression. However, this relationship was not observed with luminal expression of the gland type. The survival rate in patients with cytoplasmic CD133 expression was significantly worse than that in the CD133-negative group. This relationship was observed in the survival rate of the adjuvant chemotherapy group and the curative resection group. Multivariate analysis revealed that the expression of CD133 in the cytoplasm was an independent prognostic factor in gastric cancer. Regarding the correlation between CD133 expression and HIF-1α expression, the HIF-1α positive rate was lower in patients with CD133 luminal expression of the gland type and higher in patients with cytoplasmic expression of CD133. Conclusion Gastric cancer cells with CD133 expression in the cytoplasm were cells with high potential for malignancy, and this phenotype was associated with cancer progression, chemotherapy resistance, recurrence, and poor prognosis. Cytoplasmic expression of CD133 may be a useful prognostic marker in gastric cancer. Significant correlation was observed between HIF-1α expression and the immunohistochemical staining pattern of CD133.
    Full-text · Article · Apr 2013 · Gastric Cancer
Show more